CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Regeneron Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Regeneron Pharmaceuticals Inc
777 Old Saw Mill River Road
Phone: (781) 370-5000p:781 370-5000 TARRYTOWN, NY  10591  United States Ticker: REGNREGN
Business Summary
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. It helps in accelerating and improving the traditional drug development process through its VelociSuite technologies. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; REGEN-COV; Kevzara (sarilumab) Injection, and others. The Company’s solid tumor and other oncology and autoimmune cell therapy programs include the bbT369 program in B-NHL, SC-DARIC33 in AML, MUC16 in ovarian cancer, MAGE-A4, autoimmune, and several unnamed targets.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-YesYes--

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes-YesYes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Co-Chairman of the Board, President, Chief Executive Officer, Founder Leonard S.Schleifer 70 6/9/2023 1/1/1988
Co-Chairman of the Board, President, Chief Scientific Officer George D.Yancopoulos 63 6/9/2023 6/14/2001
Chief Financial Officer, Senior Vice President - Finance Christopher R.Fenimore 53 2/5/2024 1/1/2012
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Decibel Therapeutics, Inc. 1325 Boylston Street, Suite 500 BOSTON MA United States
Checkmate Pharmaceuticals Inc 245 Main Street, 2Nd Floor CAMBRIDGE MA United States

Business Names
Business Name
Checkmate Pharmaceuticals Inc
Checkmate Pharmaceuticals, Inc.
Decibel Securities Corporation
28 additional Business Names available in full report.

General Information
Number of Employees: 13,450 (As of 12/31/2023)
Outstanding Shares: 109,761,896 (As of 1/25/2024)
Shareholders: 167
Stock Exchange: NASD
Federal Tax Id: 133444607


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 16, 2024